{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-113828","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.800067+00:00","generated_at":"2026-06-08T23:44:21.086620+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Protagonist Q3 net loss $34.1M; earns $50M milestone from Janssen for JNJ-2113 Phase 3","bullets":["Net loss of $34.1M ($0.58 per share) vs $31.2M loss in Q3 2022; R&D expenses rose to $30.7M.","Cash, equivalents and marketable securities $322.7M as of Sep 30, 2023; cash runway through Q1 2026.","JNJ-2113 Phase 3 ICONIC-LEAD, ICONIC-TOTAL trials and Phase 2b ANTHEM-UC trial initiated in Q4 2023.","Dosing of third patient in ICONIC-LEAD triggered $50M milestone from Janssen in October 2023.","Five rusfertide abstracts accepted for oral/poster presentations at ASH 2023 annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-113828","json":"https://secwatch.observer/filing/0001104659-23-113828.json","markdown":"https://secwatch.observer/filing/0001104659-23-113828.md","text":"https://secwatch.observer/filing/0001104659-23-113828.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923113828/0001104659-23-113828-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923113828/tm2329667d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T23:44:21.086620+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"71da5709623143dd1984f6896eccda6705d22b73","claim":"Protagonist Therapeutics, Inc reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 2, 2023, Protagonist Therapeutics, Inc. reported its financial results for the third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923113828/0001104659-23-113828-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}